Cited 0 times in Scipus Cited Count

A pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis

DC Field Value Language
dc.contributor.authorYoo, DH-
dc.contributor.authorSuh, CH-
dc.contributor.authorShim, SC-
dc.contributor.authorLee, SJ-
dc.contributor.authorKim, SH-
dc.contributor.authorPark, W-
dc.date.accessioned2022-12-07T05:53:34Z-
dc.date.available2022-12-07T05:53:34Z-
dc.date.issued2020-
dc.identifier.issn1742-5255-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/23209-
dc.description.abstractINTRODUCTION: CT-P10 is the first biosimilar of rituximab (RTX) for the treatment of rheumatoid arthritis (RA). The application of valuable biosimilar for the treatment of RA may decrease economic burden of society, and disease activity of RA. Thus, it is worthwhile to identify the economic advantage and further requirement for the proper use of CT-P10 in real world.

AREAS COVERED: Literature searching was performed to identify suitable references written in English for this review article. Rituximab, biosimilar, CT-P10, and rheumatoid arthritis were used as keywords. Current state of RA treatment, position of RTX in the recommendations for the treatment of RA, current status of RTX biosimilar development were assessed before evaluating CT-P10 itself. Physicochemical property, pharmacokinetic profile through phase I to phase III studies, pharmacodynamics, toxicology data, clinical efficacy, and safety were reviewed.

EXPERT OPINION: As the first biosimilar to originator RTX, CT-P10 may be a useful alternative for the treatment of RA in all indications for originator RTX. In addition, more studies are required to identify long-term effectiveness and safety of CT-P10 in real world. It is also important to find out new indications of CT-P10 and effective mechanisms to lessen nocebo effect against biosimilar including CT-P10.
-
dc.language.isoen-
dc.subject.MESHAntibodies, Monoclonal, Murine-Derived-
dc.subject.MESHAntirheumatic Agents-
dc.subject.MESHArthritis, Rheumatoid-
dc.subject.MESHBiosimilar Pharmaceuticals-
dc.subject.MESHDrug Development-
dc.subject.MESHHumans-
dc.subject.MESHRituximab-
dc.subject.MESHTreatment Outcome-
dc.titleA pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis-
dc.typeArticle-
dc.identifier.pmid33012214-
dc.subject.keywordCT-P10-
dc.subject.keywordbiosimilar-
dc.subject.keywordpharmacokinetics-
dc.subject.keywordrheumatoid arthritis-
dc.subject.keywordrituximab-
dc.contributor.affiliatedAuthorSuh, CH-
dc.type.localJournal Papers-
dc.identifier.doi10.1080/17425255.2020.1832082-
dc.citation.titleExpert opinion on drug metabolism & toxicology-
dc.citation.volume16-
dc.citation.number12-
dc.citation.date2020-
dc.citation.startPage1125-
dc.citation.endPage1132-
dc.identifier.bibliographicCitationExpert opinion on drug metabolism & toxicology, 16(12). : 1125-1132, 2020-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1744-7607-
dc.relation.journalidJ017425255-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Rheumatology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse